Hematology
Non-O Blood Types May Be Linked to Venous Thromboembolism in Patients With Cancer
May 04, 2022
Article
New research suggests that blood type may be an easily accessible predictor of venous thromboembolism risk.
Time-Limited Ublituximab/Umbralisib Plus Ibrutinib Shows Efficacy, Tolerability in CLL
May 01, 2022
Article
The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.
Very Low-Dose RT Is Effective, Although Not Standard in Indolent Non-Hodgkin Lymphoma
April 29, 2022
Article
Very low dose radiation therapy was found to be an effective treatment approach in the palliative setting for patients with indolent non-Hodgkin lymphoma.
Ilene Galinsky Highlights Evolution of AML Treatment
April 28, 2022
Video
Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner, at Dana Farber Cancer Institute, discusses how treatment for patients with acute myeloid leukemia has evolved in recent years.
Liso-cel Exhibits Durable Responses in Relapsed-Refractory Large B-Cell Lymphoma
April 27, 2022
Article
Patients with relapsed/refractory large B-cell lymphoma continued to derive benefit from lisocabtagene maraleucel after 2 years of follow-up.
Axi-cel Sustains Long-Term Survival Rates in Relapsed/Refractory Large B-Cell Lymphoma
April 26, 2022
Article
Patients with relapsed or refractory large B-cell lymphoma experienced improved overall survival following treatment with axicabtagene ciloleucel.
Belimumab May Help Prevent Chronic GVHD in Adults Undergoing Allogenic Transplant
April 26, 2022
Article
Belimumab has emerged as a safe and tolerable agent that may be useful for the prophylaxis of chronic graft-vs-host-disease.
Newly Approved Pacritinib Continues to Reduce Symptom Burden in Myelofibrosis With Moderate/Severe Thrombocytopenia
April 20, 2022
Article
Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.
Caring for an Immunocompromised Bone Marrow Transplant Recipient
April 14, 2022
Article
Special protocols are required to ensure the safety of patients undergoing bone marrow transplants.
Adding Bispecific Antibody to Natural Killer Cells May Be Effective in Heavily Pretreated Lymphoma
April 11, 2022
Article
Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.